Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Outcome of pancreas transplants from 1966 to 2000

Pancreas transplant patient and graft survival rates have significantly improved over time as surgical techniques and immunosuppressive protocols have evolved, according to research published in April's Annals of Surgery.

News image

fiogf49gjkf04

A team from Minneapolis, Minnesota, USA, determined outcome in diabetic pancreas transplant recipients, according to risk factors and the surgical techniques and immunosuppressive protocols that evolved during a 33-year period at a single institution.

Clinical pancreas transplantation began at the University of Minnesota in 1966, initially with a high failure rate, but outcome improved in parallel with other organ transplants.

The authors retrospectively analyzed the factors associated with the increased success rate of pancreas transplants.

The surgeons performed 1,194 pancreas transplants (111 from living donors; 191 re-transplants) between 1966 and 2000. Of these, 498 were simultaneous pancreas-kidney (SPK) and 1 was a simultaneous pancreas-liver transplant. 404 were pancreas after kidney (PAK) transplants; and 291 were pancreas transplants alone (PTA).

The analyses were divided into five eras, depending on the type of immunosuppression and surgical technique used within the time periods: Era 0 (1966 to 1973), historical; Era 1 (1978 to 1986); Era 2 (1986-1994); Era 3 (1994-1998); and Era 4 (1998-2000).

In Era 1 patients underwent solitary (PAK and PTA) transplants involving multiple duct management techniques, and received cyclosporine for immunosuppression.

In Era 2, all varieties of pancreatic transplantation were performed (SPK, PAK, and PTA) with bladder drainage for graft duct management. Cyclosporine, azathioprine, and prednisone were used for immunosuppression.

In Era 3, tacrolimus and mycophenolate mofetil replaced the standard immunosuppressive regime of the previous era.

The surgical technique of Era 4 was primarily enteric drainage for SPK transplants. Daclizumab was used for induction immunosuppression; pre-transplant immunosuppression was used in candidates awaiting PTA.

Pancreas transplant should be an option at all stages of diabetes.
Annals of Surgery

One-year patient and graft survival rates were calculated for each category and era.

The patient survival following SPK transplant was 85% in Era 2, compared to 92% in Eras 3 and 4 combined. Graft survival was 64% and 79%, respectively.

In Era 1, patient and graft survival rates, following PAK transplants, were 86% and 17%, respectively. In Era 4 these figures were 98% and 81%.

PTA transplant patient and survival rates were 77% and 31%, and 100% and 88%, for Eras 1 and 4 respectively.

SPK graft survival rates were significantly higher with bladder drainage (82%) than enteric drainage (74%) at 1 year.

Increasing recipient age had an adverse effect on outcome only in SPK recipients. Vascular disease was found to be common; those with no vascular disease had significantly higher patient and graft survival rates in the SPK and PAK categories.

Living donor segmental pancreas transplants were associated with higher technically successful graft survival rates in each era.

The researchers found that pancreatic transplants reduced diabetic secondary complications in some recipients. Quality of life was improved in all patients.

Dr David Sutherland, of the University of Minnesota, said on behalf of the group, "Patient and graft survival rates have significantly improved over time as surgical techniques and immunosuppressive protocols have evolved.

"Eventually, islet transplants will replace pancreas transplants for suitable candidates, but currently pancreas transplants can be applied, and should be an option at all stages of diabetes. Early transplants are preferable for labile diabetes, but even patients with advanced complications can benefit," he concluded.

Ann Surg 2001; 233: 463-501
09 May 2001

Go to top of page Email this page Email this page to a colleague

 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us